Stradefy Biosciences

Stradefy Biosciences is developing innovative bioadhesive nanoparticles (BNPs) to deliver therapeutic agents to target tissues at maximally effective doses while reducing systemic toxicities. The Company licensed from Yale technology from the laboratories of co-founder professors Mark Saltzman and Dr. Michael Girardi with high value applications in oncology, autoimmune diseases, and other indications. ESV’s Venture Partner, Brian Dixon, served as the startup CEO. Elm Street Ventures is the lead investor. Jeff Goldberg serves as Executive Chairman.